Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 4, 2008, Pages 723-730

  Canitano, Roberto ^a   Scandurra, Valeria ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Autism; Pervasive developmental disorders; Risperidone

Indexed keywords

PLACEBO; RISPERIDONE;

AUTISM; BEHAVIOR DISORDER; CLINICAL TRIAL; COMMUNICATION DISORDER; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPERSALIVATION; HYPOKINESIA; INCREASED APPETITE; MEDICAL DOCUMENTATION; METHODOLOGY; MOTOR DYSFUNCTION; OPEN STUDY; OUTCOMES RESEARCH; REVIEW; RHINITIS; SEDATION; SIDE EFFECT; SOCIAL PROBLEM; SOMNOLENCE; STEREOTYPY; TACHYCARDIA; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 52649145928     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s1450     Document Type: Review

References (34)

1. Anderson GM, Scahill L, McCracken JT, et al. 2007. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry, 61:545-50.
2. Aman MG. 2004. Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Semin Pediatr Neurol, 11:225-8.
3. Aman MG, Singh NN, Stewart AW, et al. 1985. The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic, 89:485-91.
4. Aman MG, Tassé MJ, Rojahn J, et al. 1996. The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Res Dev Disabil, 17:41-57.
5. [APA] American Psychiatric Association. 1994. Pervasive developmental disorders. Diagnostic and Statistic Manual of Mental Disorders, 4th edition. Washington, DC: American Psychiatric Association.
6. Arnold LE, Vitiello B, McDougle C, et al. 2003. Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry, 42:1443-50.
7. Barnard L, Young AH, Pearson J, et al. 2002. A systematic review ofthe use of atypical antipsychotics in autism. J Psychopharmacol, 16:93-101.
8. Campbell M, Armenteros JL, Malone RP, et al. 1997. Neuroleptic-related dyskinesias in autistic children: a prospective longitudinal study. J Am Acad Child Adolesc Psychiatry, 36:835-43.
9. Campbell M, Rapoport J, Simpson G. 1999. Antypsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry, 38:537-45.
10. Canitano R. 2006. Self injurious behavior in autism. Clinical aspects and treatment with risperdone. J Neural Trans, 113:425-31.
11. Chavez B, Chavez-Brown M, Rey JA. 2006. Role of risperidone in children with autism spectrum disorder. Ann Pharmacother, 40:909-16.
12. Diler RS, Firat S, Avci A. 2002. An open label trial of risperidone in young children with autism. Curr Ter Res Clin Exp, 63:91-102.
13. Findling R, Kusumakar V, Daneman D, et al. 2003. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry, 64:1362-9.
14. Fisman S, Steele M. 1996. Risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol, 6:177-90.
15. Fombonne E. 2005. Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry, 66:S10:3-8.
16. Gagliano A, Germano E, Pustorino G, et al. 2004. Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol, 14:39-47.
17. Jesner O, Aref-Adib M, Coren E. 2007. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev, 24:CD005040.
18. Luby J, Mrakotsky C, Stalets MM, et al. 2006. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol, 16:575-87.
19. Malone RP, Maislin G, Choudhury MS, et al. 2002. Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry, 41:140-7.
20. Masi G, Cosenza A, Mucci M, et al. 2001. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry, 40:1206-14.
21. Masi G, Cosenza A, Mucci M, et al. 2003. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry, 64:1039-47.
22. McCracken JT, McGough J, Shah B, et al.; Research Units on Pediatric Psychopharmacology Autism Network. 2002. Risperidone in children with autism and serious behavioral problems. N Engl J Med, 347:314-21.
23. McDougle C, Holmes J, Bronson MR, et al. 1997. Risperidone treatment in children and adolescent with pervasive developmental disorders: A prospective open-label trial. J Am Acad Child Adolesc Psychiatry, 36:685-93.
24. McDougle CJ, Scahill L, Aman MG, et al. 2005. Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry, 162:1142-8.
25. Nagaraj R, Singhi P, Malhi P. 2006. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurology, 21:450-5.
26. Nicolson R, Awad G, Sloman L. 1998. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry, 37:372-6.
27. Pandina GJ, Bossie CA, Youssef E, et al. 2007. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord, 37:367-73.
28. Rausch JL, Sirota EL, Londino DL. 2005. Open-label risperidone for Asperger's disorder: negative symptom spectrum response. J Clin Psychiatry, 66:1592-7.
29. [RUPPAN] Research Units on Pediatric Psychopharmacology Autism Network. 2005. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry, 162:1361-9.
30. Schopler E, Reichler RJ, DeVellis RF, et al. 1980. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord, 10:91-103.
31. Shea S, Turgay A, Carroll A, et al. 2004. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114:e634-e641.
32. Troost PW, Lahuis BE, Steenhuis MP, et al. 2005. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry. 44:1137-44.
33. West L, Waldrop J. 2006. Risperidone use in the treatment of behavioral symptoms in children with autism. Pediatr Nurs, 32:545-9.
34. Zuddas A, Di Martino A, Muglia P, et al. 2000 Long-term risperidone for pervasive developmental disorder: efficacy, tolerability and discontinuation. J Child Adolesc Psychopharmacol, 10:79-90.